Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ROIV stock chart
Technical analysisKey statistics
All statistics- Market cap
- $28.01B
- EPS (TTM)
- -$0.65
- Dividend yield
- None
- 52-week range
- 19.96 – 42.50
- Day range
- 38.46 – 39.51
- Volume / Avg
- 3.97M / 8.13M
- Beta
- —
- Shares outstanding
- 724.56M
52-week range
ROIV stock today
Shares of Roivant Sciences (ROIV) finished lower on Nov 20 at $38.66, a drop of 0.78% or $0.305 per share, versus the S&P 500's 3.70% decline. Trading was light, with 3.97M shares changing hands, about 49% of the average daily volume. At this level, ROIV sits near the top of its 52-week range of $19.96 to $42.50: 9.0% below the high, set on Sep 8, 2026 and 93.7% above the low.
ROIV is up 78.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 91.2%. Roivant Sciences has posted a net loss over the last twelve months (EPS of -$0.65), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Roivant Sciences
Company profileRoivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Matthew Gline
- Headquarters
- London
- Employees
- 721
- Website
- roivant.com
Financial highlights
Full financialsIn fiscal 2025, Roivant Sciences generated $8.3 million in revenue, down 71.6% from fiscal 2024, its first annual decline since 2024. Roivant Sciences reported a net loss of $299.8 million, compared with a loss of $172.0 million a year earlier. Operating margin was -6235.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $8.26M | $29.05M | $32.71M | $31.53M | $55.29M |
| Growth | -71.57% | -11.19% | +3.75% | -42.97% | +132.34% |
| Net income | $-299.77M | $-171.98M | $4.35B | $-1.01B | $-845.26M |
| EPS (diluted) | $-0.54 | $-0.24 | $5.23 | $-1.42 | $-1.26 |
Analyst forecast
ForecastConsensus (13 analysts)
strong_buy
Avg. price target
$50.82+31.47%
- Strong buy 2
- Buy 9
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.27 vs $-0.52
- Surprise
- +48.08%
ROIV news
All ROIV news- Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's WhyNasdaq
- Wall Street Analysts Think Montes Archimedes Acquisition (ROIV) Could Surge 29.62%: Read This Before Placing a BetNasdaq
- Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha
- Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline MomentumSeeking Alpha
- Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA DermatologyGlobeNewswire
- Stock Indexes Surge as Buyers Return to Chipmakers and AI StocksNasdaqALK, GOOGL, AAPL, ANET
- Roivant Sciences (ROIV) Q2 2026 Earnings Call TranscriptNasdaqROIV, HEI.A
- Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call TranscriptSeeking Alpha
Roivant Sciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| INSMInsmed Incorporated | 141.33 | -2.17% | $31.01B | vs ROIV |
| GMABGenmab A/S ADS | 50.60 | -1.46% | $31.20B | vs ROIV |
| ZTSZoetis Inc. Class A | 79.11 | -2.08% | $32.14B | vs ROIV |
| UTHRUnited Therapeutics Corporation | 554.73 | -0.78% | $23.63B | vs ROIV |
| VTRSViatris Inc. | 19.63 | -1.26% | $22.50B | vs ROIV |
| ALNYAlnylam Pharmaceuticals Inc. | 143.82 | -2.71% | $19.26B | vs ROIV |
| RPRXRoyalty Pharma plc Class A | 68.45 | +1.08% | $39.36B | vs ROIV |
| ASNDAscendis Pharma A/S | 252.73 | -1.26% | $16.58B | vs ROIV |
Indexes, lists and sector
Roivant Sciences stock FAQ
What is Roivant Sciences's stock price today?
ROIV last traded at $38.66 as of Nov 20, 4:00 PM EST, down 0.78% on the day. Prices are delayed at least 15 minutes.
Who is Roivant Sciences's CEO?
Mr. Matthew Gline is the chief executive officer of Roivant Sciences Ltd., which has about 721 employees.
What is the ROIV 52-week high?
The 52-week high for ROIV is $42.50 and the 52-week low is $19.96. The stock is currently 9.0% below its high.